Patient education · Men’s sexual and hormonal health

Shockwave Therapy for Erectile Dysfunction: Promising Treatment or Still Emerging?

Low-intensity shockwave therapy is widely advertised as a way to treat the cause of erectile dysfunction rather than the symptom. The idea is biologically reasonable and the evidence is genuinely unsettled. The American Urological Association classifies it as investigational, and it is not FDA-approved for erectile dysfunction.

The short version

The AUA guideline states that low-intensity extracorporeal shock wave therapy should be considered investigational for men with ED — a Conditional Recommendation at Evidence Level Grade C.
It is not FDA-approved for erectile dysfunction. Devices used for it are generally cleared or marketed for other purposes, and clearance for another indication is not approval for this one.
European guidance is more permissive. The European Association of Urology gives it a weak recommendation for selected men with mild vasculogenic ED or poor response to PDE5 inhibitors. Two respectable bodies reading similar evidence reached different conclusions, which is itself informative.
The proposed mechanism is neovascularisation — acoustic pulses stimulating new blood vessel growth in the erectile tissue. If that is what happens, the effect would be on the underlying vascular problem rather than on a single episode.
There is no standard protocol. Energy, pulse count, session length, number of sessions and spacing all vary between devices and clinics, and much of the published literature uses focused low-intensity devices specifically. Device type matters when interpreting a claim.
Reported serious adverse events in trials are few, which is a genuine point in its favour, but low risk is not the same as demonstrated benefit.
It is paid for in cash, in a course of sessions, and is not generally covered by insurance.

What it is, and what it is supposed to do

Low-intensity extracorporeal shockwave therapy delivers acoustic pressure pulses to tissue through a handheld applicator and coupling gel. It is a much lower energy than the lithotripsy shockwaves used to break kidney stones, and it is not intended to destroy anything.

The hypothesis is that these pulses trigger a repair response in the treated tissue — release of growth factors, recruitment of progenitor cells and the formation of new small blood vessels, a process called neovascularisation. Since a large proportion of erectile dysfunction is vascular in origin, improving blood supply to the erectile tissue would in principle improve function without an on-demand drug.

That is a coherent hypothesis. The question is whether it happens to a clinically meaningful degree in real patients, and in which patients.

Where the guidelines actually stand

American Urological Association: investigational

The AUA erectile dysfunction guideline states that for men with ED, low-intensity extracorporeal shock wave therapy should be considered investigational. It is a Conditional Recommendation at Evidence Level Grade C — the lower end of both scales.

“Investigational” is a specific term. It does not mean disproven, and it does not mean unsafe. It means the evidence is not yet sufficient to establish it as a standard treatment, and that its proper home is a research setting.

European Association of Urology: weak recommendation in selected men

The EAU takes a different line, stating it may be used in men with mild organic ED or in poor responders to PDE5 inhibitors, but attaching a weak strength of recommendation.

Why the difference matters to you

When two major bodies review broadly the same literature and land in different places, the honest reading is that the evidence is not decisive. A published review comparing the guideline positions concluded that no definitive conclusion could be drawn on whether shockwave therapy achieves a clinically meaningful improvement in erectile function, and that both the EAU and AUA positions were defensible pending larger, sufficiently powered, unbiased multicentre randomised trials.

A clinic that presents this treatment as established is not describing the state of the evidence accurately.

What is genuinely unresolved

Which patients benefit. Men with mild vasculogenic ED appear the most plausible candidates. Men with severe disease, significant neurological injury, or post-prostatectomy ED are a different proposition entirely.
Which device. Focused, radial and linear devices produce and deliver energy differently. Much of the published ED literature evaluates focused low-intensity devices. A clinic using a different device type is not automatically delivering what the trials tested.
Which protocol. There is no universal schedule for energy, pulse count, sessions or spacing.
How long any benefit lasts. Durability data are limited, and the question of whether repeat courses are needed is unsettled.
How much of the reported effect is placebo. Sham-controlled trials exist and are the ones worth asking about. Erectile function endpoints are self-reported and known to be placebo-responsive.

A 2026 abridged Cochrane review of low-intensity shockwave therapy for erectile dysfunction has been published, and further systematic reviews and network meta-analyses of non-pharmacological interventions continue to appear. If you are considering this treatment, ask the clinician which recent systematic review they are relying on and what it concluded.

Questions to ask before paying for a course

Is this FDA-approved for erectile dysfunction? (The accurate answer is no.)
What does the AUA guideline say about it? (The accurate answer is investigational.)
Which device is being used, and is it the type used in the trials you are citing?
What is the protocol, how many sessions, and what is the total cost before I start?
What sham-controlled evidence supports this in someone with my cause and severity of ED?
Have I had a cardiovascular and metabolic assessment first?
What happens if it does not work — is there a refund policy, and what is the next step?

That last-but-one question is the one most often skipped. Erectile dysfunction is frequently the first sign of vascular disease. Buying a course of shockwave sessions without anyone checking your blood pressure, glucose and lipids means paying to treat a symptom while leaving the thing it was warning you about unexamined.

How to read a clinic’s evidence claims

Marketing for this treatment reuses a small number of moves. Recognising them is most of the work.

“FDA-registered” and “FDA-cleared”

Neither phrase means approved for erectile dysfunction. Establishment registration is an administrative listing. Clearance under the 510(k) pathway means a device was found substantially equivalent to an existing device for the indication it was cleared for — commonly musculoskeletal pain or wound healing. Using a cleared device for a different purpose is off-label use of the device, which is lawful for a clinician but is not an approval and is not evidence of benefit.

“Clinically proven” with a citation to a small open-label series

Erectile function is measured by self-reported questionnaire, and questionnaire outcomes are strongly placebo-responsive. A study without a sham arm cannot separate the treatment from the expectation of treatment. Ask specifically whether the cited studies were sham-controlled, and how many participants they included.

Pooled results across devices and protocols

Meta-analyses in this field combine trials using focused, radial and linear devices at different energies, pulse counts and session schedules. Pooling heterogeneous protocols can produce an impressive summary figure that describes no actual treatment anyone offers. Ask which specific protocol the clinic uses and whether it matches any trial.

Success rates without a definition

“Eighty percent success” means nothing without knowing what counted as success, in whom, and for how long. A small improvement in a questionnaire score at one month in men with mild disease is a different claim from restored function at one year in men who failed tablets.

None of this means the treatment does not work. It means the marketing is not evidence, and the distinction is the whole point of asking.

Who is least likely to benefit

The published work concentrates on men with mild to moderate vasculogenic erectile dysfunction, and that is where the EAU’s weak recommendation sits. Several groups are poorly represented in that evidence and should be especially cautious about paying for a course.

Men with severe erectile dysfunction, particularly long-standing disease with little response to maximal PDE5 inhibitor therapy.
Men whose erectile dysfunction is primarily neurological — after radical prostatectomy or pelvic radiation, or with long-duration diabetic neuropathy. A treatment hypothesised to improve blood supply does not address a damaged nerve.
Men with a significant hormonal or medication cause that has not been identified, because the treatable cause is being bypassed.
Men who have never been assessed for cardiovascular and metabolic risk. This is the group this site worries about most, because the opportunity being missed is larger than the one being purchased.
Men with Peyronie’s disease or penile implants, who need a urological assessment rather than a marketed course of sessions.

Conversely, the man for whom this is most reasonable is one with mild vasculogenic disease, an unremarkable but completed cardiovascular work-up, a partial response to tablets, realistic expectations, and money he is content to spend on something that may not work.

What the procedure actually involves

The practical experience is worth describing plainly, because clinic literature tends to skip from mechanism to results without covering the middle.

Published protocols apply a coupling gel and use a handheld applicator to deliver low-intensity acoustic pulses to defined areas of the penis, usually along the shaft and at the crura. No anaesthesia is used. Most men describe tapping, vibration, tingling, or mild discomfort rather than pain.

Session length, energy level, pulse count, and the number and spacing of sessions all depend on the device and the protocol chosen; there is no single universal schedule. A course is typically delivered over several weeks. There is generally no recovery period and no restriction on activity afterwards, which is a genuine practical advantage over more invasive options.

Published trials generally report few serious treatment-related adverse events. That is a real point in the treatment’s favour and should be stated as such. It is also the reason the risk-benefit conversation here is unusual: the question is rarely whether it will harm you, but whether it will do anything at all, and whether the money is better spent elsewhere.

Why two guideline panels reached different conclusions

The divergence between the American and European positions is not a disagreement about the data. Both panels read broadly the same literature. They differ in what they do with uncertainty, and understanding that helps you weigh the treatment yourself.

The AUA classification of investigational reflects a stance that a treatment should not be recommended for routine practice until adequately powered, unbiased, multicentre randomised evidence exists. On that view, small single-centre trials with heterogeneous protocols are a reason to keep studying, not a reason to start offering.

The EAU weak recommendation reflects a different judgement: that for a low-risk intervention in a defined group — men with mild vasculogenic disease, or poor responders to tablets who want to avoid injections or surgery — imperfect evidence of possible benefit is enough to permit an informed choice, provided the weakness of the recommendation is stated plainly.

Neither position is unreasonable, and the gap between them is precisely the size of the remaining uncertainty. What follows practically is this: if a clinic presents the treatment as established, it is misrepresenting both panels. If it presents it as one option among several, with the evidence gaps stated and a proper assessment done first, that is a defensible conversation to be having.

It also means the honest answer to “does it work?” is neither yes nor no. It is that a low-risk treatment may help some men with milder vascular disease, that nobody can yet tell you reliably whether you are one of them, and that the field has been selling it for years while that question stays open.

If you decide to proceed

Some men will reasonably choose this treatment after understanding that it is investigational. If that is you, a few conditions make it a better decision.

Complete the cardiovascular and metabolic assessment first. Not afterwards, and not instead.
Trial an established treatment first, at an adequate dose and over enough attempts, so you know what your response to first-line therapy actually is.
Get the full course price in writing before the first session, including whether any repeat or maintenance course is anticipated.
Agree in advance how response will be measured — a validated questionnaire score at baseline and at a defined follow-up, rather than an impression at the end.
Set a stopping rule. Decide before you start what result would mean you do not buy a second course.
Keep your primary clinician informed, so the underlying risk factors continue to be managed regardless of what the sessions do.

That fourth point separates a considered decision from an expensive hope. Without a baseline measurement, neither you nor the clinic can tell afterwards whether anything changed.

What it costs, and what insurance usually will not cover

We publish cost bands rather than prices. Prices vary by region, practice and contract, and a specific figure printed on a web page is wrong within months. Ask any practice for a written quotation before agreeing to treatment.

Typical band. Sold as a course of multiple sessions rather than singly, in a mid-to-high band for the full course. Advertised per-session prices multiply quickly, so ask for the total course price in writing.

What the band usually excludes. The course price typically excludes the initial evaluation, any repeat or maintenance course, PDE5 inhibitors if they are used alongside, and any cardiovascular or metabolic work-up. It also excludes the cost of the treatment that actually works if this one does not.

Coverage. Because the treatment is investigational and not FDA-approved for this indication, it is generally not covered and is paid in cash. The underlying evaluation of erectile dysfunction is ordinary medical care and is usually covered. Practices sometimes offer package pricing or financing as categories; the existence of a payment plan says nothing about whether the treatment works.

On cheaper routes. Treatment obtained abroad, devices bought online for home use, and procedures performed by unlicensed providers are all cheaper. We describe that these routes exist and why we do not guide readers to them. We do not publish sourcing instructions for them.

Not yet availableLifecycle: PROPOSED · reviewed monthly · last reviewed 2026-08-15

In development

Nothing in this section is available to you now. It is here so you can recognise the names when you meet them, not so you can seek them out.

Larger multicentre randomised trials, and systematic reviews synthesising them, continue to appear — including an abridged Cochrane review published in 2026. The open questions those trials are designed to answer are patient selection, device type, protocol standardisation and durability. Until such trials change guideline positions, the AUA classification of investigational is the operative one.